Vascular Biogenics (STU:0VB) E10: €0.00 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vascular Biogenics E10?

Vascular Biogenics STU:0VB 10 E10 is €0.00 as of Jun. 2023. GuruFocus rates STU:0VB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vascular Biogenics's adjusted earnings per share data for the three months ended in Jun. 2023 was €-0.009. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-24), Vascular Biogenics's current stock price is €0.00. Vascular Biogenics's E10 for the quarter that ended in Jun. 2023 was €0.00. Vascular Biogenics's Shiller PE Ratio of today is .


Vascular Biogenics  (STU:0VB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Vascular Biogenics E10 Related Terms


Vascular Biogenics E10 Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics E10 Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0VB vs MBIO, GNPX, LEXX: E10 Comparison

For the Biotechnology subindustry, Vascular Biogenics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Shiller PE Ratio falls into.



Vascular Biogenics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vascular Biogenics's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.009/305.1090*305.1090
=-0.009

Current CPI (Jun. 2023) = 305.1090.

Vascular Biogenics Quarterly Data

per share eps CPI Adj_EPS
201309 -0.284 234.149 -0.370
201312 -0.328 233.049 -0.429
201403 -0.303 236.293 -0.391
201406 -0.147 238.343 -0.188
201409 -1.901 238.031 -2.437
201412 -0.209 234.812 -0.272
201503 -0.139 236.119 -0.180
201506 -0.134 238.638 -0.171
201509 -0.258 237.945 -0.331
201512 -0.129 236.525 -0.166
201603 -0.189 238.132 -0.242
201606 -0.125 241.018 -0.158
201609 -0.107 241.428 -0.135
201612 -0.171 241.432 -0.216
201703 -0.178 243.801 -0.223
201706 -0.160 244.955 -0.199
201709 -0.201 246.819 -0.248
201712 0.203 246.524 0.251
201803 -0.195 249.554 -0.238
201806 -0.111 251.989 -0.134
201809 -0.129 252.439 -0.156
201812 -0.088 251.233 -0.107
201903 -0.106 254.202 -0.127
201906 -0.115 256.143 -0.137
201909 -0.127 256.759 -0.151
201912 -0.144 256.974 -0.171
202003 -0.136 258.115 -0.161
202006 -0.124 257.797 -0.147
202009 -0.102 260.280 -0.120
202012 -0.123 260.474 -0.144
202103 -0.101 264.877 -0.116
202106 -0.100 271.696 -0.112
202109 -0.077 274.310 -0.086
202112 -0.106 278.802 -0.116
202203 -0.118 287.504 -0.125
202206 -0.114 296.311 -0.117
202209 -0.121 296.808 -0.124
202212 -0.047 296.797 -0.048
202303 -0.028 301.836 -0.028
202306 -0.009 305.109 -0.009

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Vascular Biogenics (STU:0VB) has a E10 of €0.00 as of Jun. 2023. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' E10 too high?
Vascular Biogenics' current E10 is €0.00. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' E10 compare to MBIO and GNPX?
Vascular Biogenics' E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Vascular Biogenics and its competitors. Vascular Biogenics's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current E10 of €0.00. The current E10 is €0.00. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current E10 is €0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vascular Biogenics Business Description

Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.